Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 3
2018 2
2019 2
2020 1
2021 5
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. Simoes C, et al. Among authors: lavilla e. Br J Haematol. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. Epub 2023 Apr 14. Br J Haematol. 2023. PMID: 37057357 No abstract available.
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.
Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, García-Arroba Peinado J, Cid J, Jimenez MM, Valcarcel D, Gómez-Seguí I, de la Rubia J, Martin P, Goterris R, Hernández L, Tallón I, Varea S, Fernández M, García-Muñoz N, Vara M, Zarzoso MF, García-Candel F, Paciello ML, García-García I, Zalba S, Campuzano V, Gala JM, Estévez JV, Jiménez GM, López Lorenzo JL, Arias EG, Freiría C, Solé M, Ávila Idrovo LF, Hernández Castellet JC, Cruz N, Lavilla E, Pérez-Montaña A, Atucha JA, Moreno Beltrán ME, Moreno Macías JR, Salinas R, Del Rio-Garma J. Izquierdo CP, et al. Among authors: lavilla e. Blood Adv. 2022 Dec 27;6(24):6219-6227. doi: 10.1182/bloodadvances.2022008028. Blood Adv. 2022. PMID: 35930694 Free PMC article.
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, López-Pavía M, Trigo F, Martínez-Sánchez MP, Rodríguez-Gutiérrez JI, Rodríguez-Medina C, Gil C, Belmonte DG, Vives S, Foncillas MÁ, Pérez-Encinas M, Novo A, Recio I, Rodríguez-Macías G, Bergua JM, Noriega V, Lavilla E, Roldán-Pérez A, Sanz MA, Montesinos P, On Behalf Of Pethema Group. Labrador J, et al. Among authors: lavilla e. Cancers (Basel). 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. Cancers (Basel). 2022. PMID: 35565471 Free PMC article.
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF. Rodriguez-Otero P, et al. Among authors: lavilla e. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):413-420. doi: 10.1016/j.clml.2021.02.004. Epub 2021 Feb 16. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33741302
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Montesinos P. Simoes C, et al. Among authors: lavilla e. Blood Adv. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195. Blood Adv. 2021. PMID: 33560390 Free PMC article. Clinical Trial.
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, López-Lorenzo JL, Gil C, Vidriales B, Falantes JF, Serrano A, Labrador J, Sayas MJ, Foncillas MÁ, Amador Barciela ML, Olave MT, Colorado M, Gascón A, Fernández MÁ, Simiele A, Pérez-Encinas MM, Rodríguez-Veiga R, García O, Martínez-López J, Barragán E, Paiva B, Sanz MÁ, Montesinos P; PETHEMA Group. Vives S, et al. Among authors: lavilla e. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. Epub 2021 Feb 24. Cancer. 2021. PMID: 33626197 Free article. Clinical Trial.
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group. Martínez-Cuadrón D, et al. Among authors: lavilla e. Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13. Leuk Res. 2019. PMID: 30468991 Free article.
Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
González Vicent M, Díaz de Heredia C, González de Pablo J, Molina B, Regueiro A, Pérez Martinez A, Palomo P, López Corral L, García E, Fernández JM, Pérez A, Jiménez MJ, Guerreiro M, Vallejo C, Gallardo AI, López O, Benito A, Marsal J, Duarte M, Bento L, Badell I, Pedraza A, Jiménez Ubieto A, González P, Gómez Centurión I, Costilla L, Beléndez C, Esquirol A, Espigado I, Lavilla E, Díaz MÁ. González Vicent M, et al. Among authors: lavilla e. Eur J Haematol. 2021 Jun;106(6):842-850. doi: 10.1111/ejh.13618. Epub 2021 Mar 30. Eur J Haematol. 2021. PMID: 33713387 Clinical Trial.
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, Vives S, Algarra JL, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Paiva B, Barragán E, Prosper F, Sanz MÁ, Martínez-López J, Montesinos P, On Behalf Of The Programa Para El Estudio de la Terapeutica En Hemopatias Malignas Pethema Cooperative Study Group. Ayala R, et al. Among authors: lavilla e. Cancers (Basel). 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458. Cancers (Basel). 2021. PMID: 34070172 Free PMC article.
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Motlló C, et al. Among authors: lavilla e. Leuk Lymphoma. 2018 Jan;59(1):146-154. doi: 10.1080/10428194.2017.1326596. Epub 2017 May 30. Leuk Lymphoma. 2018. PMID: 28554259
20 results